Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.47 |
| ▸ | SELL | P14151 | 1/20 | 0.45 |
| ▸ | SELP | P16109 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ATIC | P31939 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6337381 | 0.83 | ALDH1A1 (0.46) | XDHSLC22A12GPR35ALDH1A1TSHR | |
| SCHEMBL3808419 | 0.79 | TSHR (0.41) | XDHSLC22A12GPR35ALDH1A1TSHR | |
| SCHEMBL3815752 | 0.79 | MRGPRX4 (0.43) | XDHSLC22A12GPR35ALDH1A1TSHR | |
| SCHEMBL6283230 | 0.79 | CA12 (0.46) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL2083799 | 0.74 | NR4A1 (0.48) | GPR35ALDH1A1TSHRCA12CA1 | |
| SCHEMBL1173895 | 0.74 | LDHA (0.61) | LDHASELLSELPALDH1A1TSHR | |
| SCHEMBL29750616 | 0.74 | LDHA (0.61) | LDHASELLSELPALDH1A1TSHR | |
| SCHEMBL6151681 | 0.73 | CA12 (0.43) | SELLSELPXDHSLC22A12GPR35 | |
| SCHEMBL7069502 | 0.72 | CXCR2 (0.48) | XDHSLC22A12ALDH1A1TSHRHPGD | |
| SCHEMBL29860525 | 0.71 | SELL (0.79) | LDHASELLSELPALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| EP-2041073-B1 | CXCR2 INHIBITORS | SANOFI SA (FR) | 2016-07-27 | — | — | EP | disclosed |
| US-8980938-B2 | CXCR2 inhibitors | SANOFI (FR) | 2015-03-17 | — | — | US | disclosed |
| US-8642643-B2 | CXCR2 antagonists | SANOFI (FR) | 2014-02-04 | — | — | US | disclosed |
| EP-2041072-B1 | CXCR2 ANTAGONISTS | SANOFI SA (FR) | 2013-09-11 | — | — | EP | disclosed |
| US-20090258936-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
| US-20090258906-A1 | CXCR2 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-10-15 | — | — | US | disclosed |
| EP-2041073-A1 | CXCR2 INHIBITORS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| EP-2041072-A1 | CXCR2 ANTAGONISTS | Sanofi-Aventis (FR) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008000410-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
| WO-2008000408-A1 | CXCR2 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258936-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR3 | LDHA 2945/4885SELL 82/4885SELP 340/4885 |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | LDHA 3966/4885SELL 4638/4885SELP 4518/4885 |
| US-20090258906-A1 | CXCR2 ANTAGONISTS | CXCR2, CXCR1, CXCR3 | LDHA 3088/4885SELL 86/4885SELP 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.